Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors PTC Therapeutics
- 24 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2019 Planned End Date changed from 29 Feb 2020 to 24 Mar 2020.
- 15 Mar 2019 Planned primary completion date changed from 29 Feb 2020 to 24 Mar 2020.